The future of drugs distribution in the National Health System
DOI:
https://doi.org/10.33393/grhta.2024.2619Keywords:
Affiliated distribution, Direct distribution (DD), Direct Distribution Handbook (PHT), Distribution on behalf (DPC), Pharmaceutical distributionAbstract
The distribution of drugs reimbursed by the NHS in Italy can be summarized in three forms: direct (DD), on behalf of (DPC) and affiliated. The following document presents the results of the discussion of a multidisciplinary experts’ panel, from different professional realities in the healthcare system, on alternative methods of drugs’ distribution. It was highlighted how regional autonomy has led to extremely innovative experiences but also to a lack of homogeneity regarding the access to pharmaceutical assistance across Italy. The main recommendations developed by the experts can be summarized as follows:
- To ensure decisions regarding prescription and classification, with respect to the healthcare delivery settings, with the consequent distribution model and purchasing processes, is AIFA’s responsibility.
- To evaluate the reclassification of drugs from class H to class A-PHT for drugs intended to be taken at patient’s home, in cases where close monitoring by specialistic structures is not necessary.
- To limit the inclusion of a drug in PHT to conditions of differential diagnostic complexity, need for recurrent patient’s referral to the healthcare facility, presence of AIFA monitoring register, settings of drugs’ administration (home hospitalization and home care).
- In the field of PHT drugs, AIFA should, with the support of a multidisciplinary technical table:
- Update the list periodically.
- Identify the drugs on the list for which DD is preferential, leaving the others in DPC.
- Evaluate the conditions to transfer some drugs to distribution under an agreement.
Downloads
References
Osservatorio Farmaci Cergas, Università Bocconi. Report n. 42 – Report annuale per il 2021 https://cergas.unibocconi.eu/sites/default/files/media/attach/Report_42_OSFAR.pdf?VersionId=GYOF5OutqeWJfurQQS7lTrm8geUFqQmm (Accessed March 2023)
Agenzial Italiana del Farmaco (AIFA). Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei Farmaci in Italia. Rapporto Nazionale Anno 2021. Roma: Agenzia Italiana del Farmaco. 2022. https://www.aifa.gov.it/documents/20142/1740782/Rapporto-OsMed-2021.pdf (Accessed March 2023)
Agenzia Italiana del Farmaco (AIFA). Monitoraggio della Spesa Farmaceutica Nazionale e Regionale gennaio-dicembre 2021- Consuntivo (14/7/2022) https://www.aifa.gov.it/documents/20142/1517124/Monitoraggio_Spesa_gennaio-dicembre-2021_consultivo.pdf (Accessed March 2023)
Rega C, Gamberini L, De Rosa M. Analisi dei costi di servizio per confezione dei farmaci in PHT relativi alle differenti modalità distributiva: diretta e per conto. Giornale Italiano di Farmacia Clinica. 2010;4:439-447. https://www.farmaciaclinica.it/archivio/1094/articoli/12074/ (Accessed March 2023)
Jommi C, Bianco A, Chiumente M, Valinotti G, Cattel F. Il costo della distribuzione diretta dei farmaci in dieci aziende sanitarie piemontesi. Giornale italiano di Farmacia clinica,. 2015;3: 152-169-. https://www.farmaciaclinica.it/archivio/2016/articoli/21938/ (Accessed March 2023)
Jommi C, Paruzzolo S. Il costo della distribuzione diretta dei farmaci: analisi del caso Umbria. Economia e politica del farmaco 2005;5:23-9.
Garlatti A, Bruni V. Distribuzione dei farmaci: gestione diretta o tramite farmacie? Materiali e metodi da un caso aziendale. MECOSAN. 2015;2014(91):81-104. https://www.francoangeli.it/Riviste/Scheda_Rivista.aspx?IDArticolo=52781&Tipo=Articolo%20PDF&lingua=IT&idRivista=180 (Accessed March 2023) DOI: https://doi.org/10.3280/MESA2014-091005
Armeni P, Bertolani A, Costa F, Jommi C, Otto M. Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distrubozione dei farmaci in Rapporto OASI 2017, Cergas (Eds), Egea, Chap 14: pp 503-533.
Published
How to Cite
License
Copyright (c) 2024 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
Accepted 2023-11-30
Published 2024-01-15
